Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line

被引:15
作者
Annab, LA [1 ]
Hawkins, RE [1 ]
Solomon, G [1 ]
Barrett, JC [1 ]
Afshari, CA [1 ]
机构
[1] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA
来源
BREAST CANCER RESEARCH | 2000年 / 2卷 / 02期
关键词
antisense; BRCA1; cell death; estrogen; ovarian cancer; proliferation;
D O I
10.1186/bcr45
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We tested the hypothesis that BRCA1 may play a role in the regulation of ovarian tumor cell death as well as the inhibition of ovarian cell proliferation. Introduction of BRCA1 antisense retroviral constructs into BG-1 estrogen-dependent ovarian adenocarcinoma cells resulted in reduced BRCA1 expression. BRCA1 antisense pooled populations and derived subclones were able to proliferate in monolayer culture without estrogen, whereas control cells began to die after 10 days of estrogen deprivation. In addition, both populations and subclones of BRCA1 antisense infected cells demonstrated a growth advantage in monolayer culture in the presence of estrogen and were able to proliferate in monolayer culture without estrogen, while control cells did not. Furthermore, clonal studies demonstrated that reduced levels of BRCA1 protein correlated with growth in soft agar and greater tumor formation in nude mice in the absence of estrogen. These data suggest that reduction of BRCA1 protein in BG-1 ovarian adenocarcinoma cells may have an effect on cell survival during estrogen deprivation both in vitro and in vivo.
引用
收藏
页码:139 / 148
页数:10
相关论文
共 61 条
  • [21] CHARACTERIZATION OF THE HUMAN CYCLOPHILIN GENE AND OF RELATED PROCESSED PSEUDOGENES
    HAENDLER, B
    HOFER, E
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 190 (03): : 477 - 482
  • [22] The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse
    Hakem, R
    delaPompa, JL
    Sirard, C
    Mo, R
    Woo, M
    Hakem, A
    Wakeham, A
    Potter, J
    Reitmair, A
    Billia, F
    Firpo, E
    Hui, CC
    Roberts, J
    Rossant, J
    Mak, TW
    [J]. CELL, 1996, 85 (07) : 1009 - 1023
  • [23] Growth retardation and tumour inhibition by BRCA1
    Holt, JT
    Thompson, ME
    Szabo, C
    RobinsonBenion, C
    Arteaga, CL
    King, MC
    Jensen, RA
    [J]. NATURE GENETICS, 1996, 12 (03) : 298 - 302
  • [24] A SOMATIC BRCA1 MUTATION IN AN OVARIAN TUMOR
    HOSKING, L
    TROWSDALE, J
    NICOLAI, H
    SOLOMON, E
    FOULKES, W
    STAMP, G
    SIGNER, E
    JEFFREYS, A
    [J]. NATURE GENETICS, 1995, 9 (04) : 343 - 344
  • [25] Tumour biological features of BRCA1-induced breast and ovarian cancer
    Johannsson, OT
    Idvall, I
    Anderson, C
    Borg, A
    Barkardottir, RB
    Egilsson, V
    Olsson, H
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) : 362 - 371
  • [26] Regulation of ovarian follicle atresia
    Kaipia, A
    Hsueh, AJW
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1997, 59 : 349 - 363
  • [27] Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO
  • [28] 2-Y
  • [29] SPONTANEOUS APOPTOSIS OF CELLS PREPARED FROM THE NONREGRESSING CORPUS-LUTEUM
    KENNY, N
    WILLIAMS, RE
    KELM, LB
    [J]. BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1994, 72 (11-12): : 531 - 536
  • [30] Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
    Ludwig, T
    Chapman, DL
    Papaioannou, VE
    Efstratiadis, A
    [J]. GENES & DEVELOPMENT, 1997, 11 (10) : 1226 - 1241